Dr. Nooka presents a comprehensive treatment algorithm for 100 patients with relapsed multiple myeloma, providing clear ...
Dr. Nooka presents a case-based approach to treatment selection using a 50-year-old woman with relapsed/refractory multiple myeloma who progressed after 15 months on lenalidomide maintenance following ...
With the emergence of antibody-drug conjugates, the genitourinary cancers space is rapidly evolving. Robert L. Ferris, MD, ...
The conversation highlights how AI is redefining what it means to be a medical expert. Pattern Recognition: Modern expertise ...
New analysis of 2304 patients shows CD19 CAR T-cell therapy efficacy is consistent across races, with outcomes driven by ...
In this segment focused on advanced renal cell carcinoma, Dr. Geynisman shifts the discussion to patients with intermediate ...
Dr. Costa emphasizes that absence of prior BCMA-directed therapy and treatment history represent fundamental elements guiding ...
New European LeukemiaNet AML minimal residual disease (MRD) guidelines provide clearer, user-friendly clinical ...
The oral FGFR2 inhibitor lirafugratinib is being reviewed by the FDA for the second-line treatment of cholangiocarcinoma ...
The FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-α (FRα), for ...
Determining optimal treatment sequencing after frontline therapy in advanced urothelial carcinoma falls into 2 categories: ...
Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results